A Phase IIb Study of OligoG in Subjects With Cystic Fibrosis

NCT ID: NCT02157922

Last Updated: 2018-04-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 65 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-10-31
• Study Completion Date: 2017-09-30

Brief Summary

The purpose of the study is assessment of efficacy and safety of OligoG as a dry powder formulation, in adult subjects with cystic fibrosis.

Detailed Description

The primary objective is to demonstrate efficacy of inhaled OligoG measured by FEV1, and supported by secondary endpoints including Mucociliary Clearance, rheology,microbiology and Quality-of-Life.

The secondary objectives are

1. To demonstrate the safety and tolerability of inhaled OligoG as a dry powder for inhalation after multiple dose administration; and

2. To evaluate patient compliance with treatment.

The design will be randomized, double-blind, placebo-controlled, multi-center, cross-over phase II study. Mucociliary and Cough clearance (MCC) will be an exploratory endpoint in a subset of 24 patients, and Lung Clearance Index (LCI) an exploratory endpoint in another subset of 20 or more patients.

Conditions

Cystic Fibrosis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Alginate oligosaccharide

Inhalation of a dry powder OligoG in the first treatment period, and of placebo the second period

Group Type: ACTIVE_COMPARATOR

alginate oligosaccharide

Intervention Type: DRUG

Inhalation

Placebo

Inhalation of placebo dry powder in the first treatment period, and OligoG in the second period

Group Type: PLACEBO_COMPARATOR

alginate oligosaccharide

Intervention Type: DRUG

Inhalation

Interventions

alginate oligosaccharide

Inhalation

Intervention Type: DRUG

Other Intervention Names

OligoG

Eligibility Criteria

Inclusion Criteria

• Male or female with a confirmed diagnosis of cystic fibrosis defined by:

1. Clinical features consistent with the diagnosis of CF AND Sweat chloride ≥60 mmol/L by pilocarpine iontophoresis; OR

2. Genotypic confirmation of CFTR mutation

• Aged 18 years or older
• Positive microbiological finding of Pseudomonas aeruginosa in expectorated sputum or cough swab within 24 months prior to Screening
• FEV1 between 40%-100%
• At Screening no clinical or laboratory findings suggestive of significant pulmonary illness, other than CF
• Female subjects of child bearing potential and sexually active male subjects must use contraception
• Provision written informed consent

Exclusion Criteria

• Changes in underlying therapy within the 14 days prior to Day 0. Subjects must be willing to remain on the same underlying stable therapy regimens for the duration of the study until the final follow-up visit.
• Changes in physiotherapy technique or schedule within 14 days prior to Day 0.
• Prohibited medications within 7 days prior to Day 0.
• Pulmonary exacerbation within 28 days of Screening.
• Positive microbiological finding of Burkholderia sp. in expectorated sputum or cough swab documented within 12 months prior to Screening.
• Lactose intolerance/milk allergy.
• On-going acute illness. Subjects must not have needed an outpatient visit, hospitalization or required any change in therapy for other pulmonary disease between Screening and Day 0.
• History of, or planned organ transplantation.
• Treatment for Allergic bronchopulmonary aspergillosis (ABPA).
• Requirement for continuous (24 hour/day) oxygen supplementation.
• Diagnosed with the G551D-mutation, and currently on concomitant treatment with Ivacaftor (Kalydeco).
• Concomitant administration of inhaled mannitol or hypertonic saline within 7 days prior to Day 0 (Visit 2).
• Initiation of cycled, inhaled tobramycin (TOBI) and Colistin less than 4 months prior to Screening (Visit 1). Note: Chronic TOBI and Colistin users are allowed to participate in this study, but subjects who have recently initiated chronic TOBI or Colistin should have at least 2 cycles of TOBI or Colistin respectively in the preceding 4 months before being enrolled in this study. Treatment should be phased in line with the antibiotic treatment.
• Concomitant use of all other marketed antibiotic agents is permitted, providing subjects are willing to remain on the same regimens within the 28 days immediately prior to Day 0 and for the entire duration of the study (until the follow-up visit).
• Clinically significant abnormal findings on haematology or clinical chemistry. In addition, any value ≥ 3 x the upper limit of normal will exclude the subject from participating in the study.
• Subjects unable to perform pulmonary function tests according to the ATS/ERS criteria.
• Pregnant or breast-feeding women. A negative urine pregnancy test must be demonstrated in females of child-bearing potential (Section 4.2.9) at Screening.
• Subjects who have participated in any interventional clinical trial within the 28 days prior to Day 0 (Visit 2).
• Subjects with documented or suspected, clinically significant, alcohol or drug abuse.
• Current malignant disease (with the exception of basal cell carcinoma and cervical neoplasia).
• Any serious or active medical or psychiatric illness, which in the opinion of the Investigator, would interfere with subject treatment, assessment, or compliance with the protocol.
• DPI intolerance, active or placebo

For MCC sites only:

• Smoking. A negative Cotinine test must be demonstrated at Screening
• Subjects who have any non-removable metal objects such as metal plates, screws etc in their head, neck, chest or abdominal area
• Subjects for whom participation in this study will exceed the limits of total radiation exposure allowed in any 12 month period (5 mSv), or will exceed 10 mSv over any three year period.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Eurostars

OTHER

Sponsor Role: collaborator

Smerud Medical Research International AS

OTHER

Sponsor Role: collaborator

AlgiPharma AS

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Tacjana Pressler, PhD MD

Role: PRINCIPAL_INVESTIGATOR

Rigshospitalet, Denmark

Locations

Rigshospitalet

Copenhagen, , Denmark

Pediatric Pulmonology and Immunology, Charité Universitätsmedizin

Berlin, , Germany

CF Zentrum Köln, Universitätskrankenhaus Köln

Cologne, , Germany

Medizinische Klinik I, Pneumologie, Uniklinik

Frankfurt, , Germany

Klinik für Pneumologie, CF-Ambulanz

Hanover, , Germany

Mukoviszidose-Zentrum für Erwachsene, Med. Klinik V-Innenstadt (LMU)

Münich, , Germany

Pneumologische Praxis Pasing

Münich, , Germany

Center for Pediatric Clinical Studies,

Tübingen, , Germany

Oslo University Hospital

Oslo, , Norway

CF-mottagningen, Sahlgrenska Universitetssjukhuset

Gothenburg, , Sweden

Stockholm CF-center, Karolinska Universitetssjukhuset

Stockholm, , Sweden

Regional Respiratory Centre, Belfast City Hospital

Belfast, , United Kingdom

Papworth Hospital

Cambridge, , United Kingdom

Bio-Images Research Ltd, Basement Medical Block, Within GRI

Glasgow, , United Kingdom

Liverpool Heart and Chest Hospital

Liverpool, , United Kingdom

Royal Brompton and Harefield NHS Foundation Trust

London, , United Kingdom

Queens Medical Centre

Nottingham, , United Kingdom

Southampton General Hospital

Southampton, , United Kingdom

Countries

Denmark; Germany; Norway; Sweden; United Kingdom

References

Hurley MN, Smith S, Forrester DL, Smyth AR. Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis. Cochrane Database Syst Rev. 2020 Jul 16;7(7):CD008037. doi: 10.1002/14651858.CD008037.pub4.

Reference Type: DERIVED

PMID: 32671834 (View on PubMed)

Other Identifiers

SMR-2984

Identifier Type: -

Identifier Source: org_study_id